The search for an HIV prevention vaccine

The search for an HIV prevention vaccine features

• 

  The monkeys’ tale: how a vaccine might nip HIV in the bud

  Four dozen rhesus monkeys may have successfully fought off the monkey equivalent of HIV in a series of trials of what looks like the most powerful candidate...

  From:  HIV treatment update

• 

  The monkeys’ tale – how a vaccine might nip HIV in the bud

  Four dozen rhesus monkeys may have successfully fought off the monkey equivalent of HIV in a series of trials of what looks like the most powerful candidate...

  From:  News

• Low levels of innate immune activation and high levels of gut antibodies may protect people from HIV

  Several research papers published in the last month have reported strong correlations between specific immune responses and protection against HIV infection or its effects. These include...

  From:  News

• 

  What about a vaccine?

  There are two ultimate solutions to HIV: a cure and a vaccine. We cover research towards a cure in this issue. But how is the search for...

  From:  HIV treatment update

• 

  Can we create ‘elite controllers’?

  Is combination immunotherapy the future? ask Edwin J Bernard and Derek Thaczuk ...

  From:  HIV treatment update

The search for an HIV prevention vaccine news from aidsmap

• Promising HIV vaccine to be tested with gay men and trans people

  A new phase III HIV vaccine trial will soon be underway for men who have sex with men and transgender people. The study, called Mosaico, will evaluate a four-shot regimen of a vaccine designed to provide protection against the ...

  22 July 2019 | Liz Highleyman

• Scientists achieve the first proof of concept for an HIV broadly neutralising antibody vaccine in monkeys

  In a step forward in the search for an HIV vaccine, Professor Denis Burton and colleagues from the Scripps Institute in La Jolla, California have manufactured an HIV vaccine that, with just one shot, induced six out of 12 ...

  02 January 2019 | Gus Cairns

• First large HIV prevention trial using antibodies will probably not be the last

  The HIV Research for Prevention conference (HIVR4P 2018) in Madrid last week was dominated by studies of one type of molecule – broadly neutralising antibodies (bNAbs). These complex molecules, which develop in some people with HIV ...

  29 October 2018 | Gus Cairns

• The Miami monkey cured with two antibodies

  A ‘functional cure’ of HIV has been achieved in one monkey given gene therapy that induced it to make two broadly neutralising antibodies against the virus. Researcher José Martinez-Navio of the University of Miami told the HIV ...

  26 October 2018 | Gus Cairns

• Will an HIV vaccine that protected two-thirds of monkeys do the same for humans?

  The Lancet last Friday published the 52-week results of APPROACH, an HIV vaccine whose 28-week results, reported by aidsmap.com last year, were sufficiently impressive for it to be taken forward into a human efficacy trial among 2600 young ...

  13 July 2018 | Gus Cairns

• European Cure Review concentrates on HIV therapeutic vaccines

  A cure for HIV would almost inevitably have to involve a vaccine to improve the body’s natural ability to control HIV, a seminar on European HIV cure research heard recently. The STEPS seminar, held by the European AIDS Treatment ...

  16 November 2017 | Gus Cairns

• Another HIV vaccine efficacy trial will start this year

  A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study would start in South Africa. HVTN 702, now running, is only the ...

  26 July 2017 | Gus Cairns

• Spanish vaccine induces viral control off ART in nearly 40% of recipients

  A so-called ‘HIV Conserv’ vaccine has, for the first time, produced significant prolonged viral control in a large minority of recipients once they were taken off antiretroviral therapy (ART). So far, one participant has stayed off ART for seven ...

  17 February 2017 | Gus Cairns

• Huge diversity in current HIV vaccine research, Research for Prevention conference hears

  The HIV vaccine research field is currently going through probably its most fertile and diverse period yet, the second HIV Research for Prevention conference (HIVR4P) in Chicago heard last week. A high proportion of presentations there were devoted ...

  23 October 2016 | Gus Cairns

• It’s all go for a new HIV vaccine efficacy trial this year

  A new efficacy trial for a vaccine to prevent HIV infection – only the seventh ever conducted in the history of the epidemic – will start this November, the 21st International AIDS Conference (AIDS 2016) heard today. The ...

  19 July 2016 | Gus Cairns

More news

The search for an HIV prevention vaccine news selected from other sources

• China to launch clinical trial of long-lasting HIV vaccine: paper

  Chinese scientists will begin the second-phase clinical trial of an HIV vaccine on 160 volunteers, Friday's China Daily reported. The candidate vaccine, DNA-rTV, relies on replication of the DNA of HIV to stimulate effective immunization.

  20 July 2019 | Xinhua

• HIV Vaccine Trials on Gay, Bi Men to Begin in U.S., Europe

  Around 3800 men who have sex with men will be part of Johnson & Johnson's historic vaccine trial.

  15 July 2019 | Advocate.com

• J&J’s Quest for Elusive HIV Vaccine Is Poised for Major Test

  Johnson & Johnson is preparing to test an experimental HIV vaccine in the U.S. and Europe in a move toward developing the first immunization against the deadly disease after decades of frustration.

  15 July 2019 | Bloomberg

• Scripps Research-led consortium receives $129 million NIH award to bring new HIV vaccination approach into clinical testing

  The candidate vaccine products are designed to be administered in multiple stages to induce immune system proteins called broadly neutralizing antibodies (bnAbs). In multiple animal studies, bnAbs have been shown to provide long-lasting protection against exposure to multiple HIV strains.

  12 July 2019 | Scripps Institute

• HVTN's large-scale HIV vaccine efficacy trials fully enrolled

  The HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center, has fully enrolled its four ongoing large-scale HIV vaccine efficacy trials. The clinical trials, underway on four continents in 12 countries, are made possible by 12,669 study participants and the collaborative efforts of HVTN study teams, all on a journey to find a safe and effective HIV vaccine. Complete enrollment facilitates the collection and analysis of trial-specific data, enabling researchers to answer research questions.

  24 June 2019 | HIV Vaccine Trials Network

• Low trust in vaccines 'a global crisis'

  Public mistrust of vaccines means the world is taking a step backwards in the fight against deadly yet preventable infectious diseases, warn experts. A Wellcome Trust analysis includes responses from more than 140,000 people in over 140 countries. Eastern Europe was the world region most sceptical of vaccines, with only 50% of people confident vaccines were safe, with Western Europe in second place, at 59%. People in France were also among the most likely to disagree that vaccines were effective, at 19%, and to disagree that vaccines were important for children to have, at 10%. The World Health Organization lists vaccine hesitancy as one of the top 10 threats to global health.

  19 June 2019 | BBC

• The three big studies pushing at the frontiers of HIV prevention

  These trials are being conducted under the auspices of the HIV Vaccine Trials Network. The network currently runs 49 clinical trial sites in nine countries with 18 ongoing trials, four of which are efficacy trials. Three trials are of particular interest as they have already been running since 2016 and are expected to close in late 2021.

  16 June 2019 | The Conversation

• Johnson & Johnson Announces Full Enrollment in Proof-of-Concept Efficacy Study of Janssen’s Investigational HIV Preventive Vaccine

  Phase 2b efficacy study of mosaic-based vaccine successfully enrolls 2,600 women aged 18-35 across five southern African countries

  31 May 2019 | Janssen press release

• Will a vaccine crisis of confidence impact the global response to HIV?

  Mitchell Warren of AVAC: "The implications of the anti-vaccination movement are enormous. Just as vaccines against some of the greatest global killers finally come within reach, fear and misinformation could diminish vital commitments to continued vaccine research, and important investments in vaccine education and delivery."

  20 May 2019 | Science Speaks

• Despite Uptick, Black and Latinx People Have Relatively Low Participation in HIV Vaccine Trials

  Black and Latinx people historically have not willfully participated in clinical trials in high numbers. Medical mistrust of research and health care institutions has long been a problem for conducting biomedical research. So what's causing the racial disparities in research participation, and what are researchers doing about it?

  14 May 2019 | The Body Pro

More news